We are live on ! Find out more
MBOT icon

Microbot Medical

22 hedge funds and large institutions have $265K invested in Microbot Medical in 2016 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

35% less funds holding

Funds holding: 3422 (-12)

75% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 16

91% less capital invested

Capital invested by funds: $3.11M → $265K (-$2.84M)

Holders
22
Holders Change
-12
Holders Change %
-35.29%
% of All Funds
0.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
5
Closed
16
Calls
Puts
Net Calls
Net Calls Change

MBOT Hedge Fund Activity: Q2 2016 in Review

22 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q2 2016, worth a combined $265K — down 91% from $3.11M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of MBOT and 4 opened new positions — a net loss of 12 holders — while 5 trimmed existing stakes and 4 added.

The largest buyer was Virtu KCG Holdings, adding an estimated $154K. The largest seller was Anson Funds Management, exiting entirely with an estimated $854K sold.

  • 22 institutional investors held Microbot Medical (MBOT) as of Q2 2016, down from 34 in Q1 2016.
  • Funds reported $265K of Microbot Medical stock for Q2 2016, down 91% quarter-over-quarter.
  • 4 funds opened new Microbot Medical positions in Q2 2016 and 16 closed out, a net change of -12 holders.
  • The largest Microbot Medical buyer in Q2 2016 was Virtu KCG Holdings, an estimated $154K added.
  • The largest Microbot Medical seller in Q2 2016 was Anson Funds Management, an estimated $854K sold.

Based on aggregated 13F filings for Q2 2016.